Table 1.

Characteristics of studies reported clinicopathological characteristics between CLDN18-ARHGAP fusion and gastric cancers.

Study	Country	Period	Samples	Lauren Type			CLDN18-ARHGAP Fusion positive			Tumor stage	Examine methods	NOS#	Special Characteristics
				N = (%)			N = (%)
				DGC*	IGC	NA	All	DGC	IGC
Nakayama et al. (7)	Japan	2006–2015	146	136 (93.2)	10 (6.8)	NA	22 (15.1)	22 (16.2)	0 (0.0)	I–IV	Fusion-FISH, RNA-seq	7	Young age
													Patients (≤ 40)
Shu et al. (6)	China	2009–2014	829	358 (43.2)	154 (18.6)	317 (38.2)	73 (8.8)	55 (15.4)	2 (1.3)	I–IV	WGS, RT-PCR	8	Fusion related to the proportion of SRCC
Tanake et al. (8)	Japan	2000–2013	254	172 (67.7)	82 (32.3)	0	26 (10.2)	22 (12.8)	4 (4.9)	I–IV	RT-PCR, FISH	6	Fusion-positive DGCs E-cad expression
Yang et al. (9)	Korea	2003–2017	384	384 (100.0)	0	0	17 (4.4)	17 (4.4)	0	I–IV	RT-PCR, RNA seq	6	Fusion related to H. pylori infections
TCGA (4)	United State	NM	295	88 (29.8)	196 (66.4)	11 (3.7)	13 (4.4)	10 (11.4)	2 (1.0)	I–IV	WGS or RNA-seq	8	Fusion related to GS tumors

^*Included mixed type.

^#NOS, The Newcastle-Ottwa Scale (11).

DGC, diffuse gastric cancer; IGC, intestinal gastric cancer; TCGA, The Cancer Genome Atlas; WGS, whole-genome sequence; RNA-seq, RNA sequence; RT-PCR, reverse transcription-polymerase chain reaction; FISH, fluorescence in situ hybridization, SRCC, signet ring cell cancer; GS, genomically stable; NA, not applicable; NM, not mentioned.